Longevity Capital

Longevity Capital invests exclusively in companies developing therapeutics that target the fundamental biology of aging. Rather than focusing on a single disease area, the firm backs platforms capable of addressing multiple age-related conditions by intervening in core aging mechanisms such as cellular senescence, epigenetic alteration, and mitochondrial decline. This approach to geroscience positions the portfolio for indications ranging from osteoarthritis to neurodegenerative diseases under a unified biological framework.

Longevity Capital structures its deployment as direct equity investments in biotechnology companies, participating in venture rounds alongside specialist life science fund managers. The firm also selectively engages in distributed development models, where a parent company incubates multiple subsidiary programs against distinct aging pathways. Longevity Capital does not publicly operate as a fund-of-funds or open its own vehicles to external limited partners.

Public records and trade publication reporting identify Longevity Capital as a participant in funding rounds for Unity Biotechnology, a company developing senolytic medicines to clear senescent cells, and Cambrian Biopharma, a holding company structure that builds multiple subsidiary programs targeting different hallmarks of aging. Both investments place the firm squarely within the translational geroscience sector, backing human clinical-stage programs rather than preclinical longevity platforms.

Longevity Capital's deal flow originates from its scientific networks within academic geroscience and the broader aging biology research community. The firm co-invests alongside specialist venture firms including ARCH Venture Partners and Longitude Capital, leveraging those relationships for diligence and access. This academic-venture hybrid sourcing model differs from generalist family offices that rely on placement agents or wealth management platforms for biotech exposure.

Based on its investment activity and operating posture, Longevity Capital operates as a principal investment entity consistent with a single-family office structure, deploying proprietary capital rather than managing third-party funds. The firm does not publicly market itself as a multi-family office, registered investment advisor, or venture capital fund manager, and no external fundraising activity has been reported.